{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:33:30Z","timestamp":1763346810403,"version":"3.40.4"},"publisher-location":"Vienna","reference-count":194,"publisher":"Springer Vienna","isbn-type":[{"type":"print","value":"9783211829592"},{"type":"electronic","value":"9783709168462"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1997]]},"DOI":"10.1007\/978-3-7091-6846-2_15","type":"book-chapter","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T05:54:24Z","timestamp":1349070864000},"page":"175-204","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of behavioural disturbances in Parkinson\u2019s disease"],"prefix":"10.1007","author":[{"given":"F.","family":"Valldeoriola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. A.","family":"Nobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/jnnp.37.2.121","volume":"37","author":"ML Albert","year":"1974","unstructured":"Albert ML, Feldman RG, Willis A (1974) The \u201csubcortical dementia\u201d of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 37: 121\u2013130.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0091-3057(88)90217-1","volume":"29","author":"S Algeri","year":"1988","unstructured":"Algeri S, De Luigi A, De Simoni MG, et al. (1988) Multiple and complex effects of buspirone on central dopaminergic system. Psychopharmacol Biochem Behav 29: 823\u2013826.","journal-title":"Psychopharmacol Biochem Behav"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ana.410330515","volume":"33","author":"T Akai","year":"1993","unstructured":"Akai T, Yamaguchi M, Mizuta E, Kuno S (1993) Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 33: 507\u2013511.","journal-title":"Ann Neurol"},{"key":"15_CR4","volume-title":"Diagnostic and statistical manual of mental disorders, 3rd edn, rev","author":"American Psychiatric Association, Committee of Nomenclature and Statistics","year":"1987","unstructured":"American Psychiatric Association, Committee of Nomenclature and Statistics (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, rev. American Psychiatric Association, Washington DC."},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0006-3223(88)90022-4","volume":"23","author":"GD Anderson","year":"1988","unstructured":"Anderson GD, Rebec GV (1988) Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment. Biol Psychiatry 23: 497\u2013506.","journal-title":"Biol Psychiatry"},{"key":"15_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF00177743","volume":"336","author":"R Andrade","year":"1987","unstructured":"Andrade R, Nicoli RA (1987) Novel anxyolitics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Arch Pharmacol 336: 5\u201310.","journal-title":"Arch Pharmacol"},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1056\/NEJM199103143241107","volume":"324","author":"RJ Baldessarini","year":"1991","unstructured":"Baldessarini RJ, Frankenburg FR (1991) Clozapine, a novel antipsychotic drug. N Engl J Med 324: 746\u2013754.","journal-title":"N Engl J Med"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/0006-8993(92)90754-W","volume":"579","author":"RJ Baldessarini","year":"1992","unstructured":"Baldessarini RJ, Marsh ER, Kula NS (1992) Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions. Brain Res 579: 152\u2013156.","journal-title":"Brain Res"},{"key":"15_CR9","first-page":"791","volume":"101","author":"A Barbeau","year":"1969","unstructured":"Barbeau A (1969) L-dopa therapy in Parkinson\u2019s disease: a critical review of nine years\u2019 experience. J Can Med Assoc 101: 7791\u2013800.","journal-title":"J Can Med Assoc"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archpsyc.1989.01810030049007","volume":"46","author":"LR Baxter","year":"1989","unstructured":"Baxter LR, Schwartz JM, Phelps ME, et al. (1989) Reduction of prefrontal glucose metabolism common to three types of depression. Arch Gen Psychiatry 46: 243\u2013250.","journal-title":"Arch Gen Psychiatry"},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/archneur.1971.00490020063007","volume":"25","author":"JV Beardsley","year":"1971","unstructured":"Beardsley JV, Puletti F (1971) Personality (MMPI) and cognitive (WAIS) changes after levodopa treatment: occurrence in patients with Parkinson\u2019s disease. Arch Neurol 25: 145\u2013150.","journal-title":"Arch Neurol"},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/archneur.1980.00500520053008","volume":"37","author":"BL Beasley","year":"1980","unstructured":"Beasley BL, Nutt JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa associated psychiatric disturbances. Arch Neurol 37: 155\u2013156.","journal-title":"Arch Neurol"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck AT, Ward CH, Mandelson M, Mock M, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561\u2013571.","journal-title":"Arch Gen Psychiatry"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/jnnp.55.7.566","volume":"55","author":"CA Biggins","year":"1992","unstructured":"Biggins CA, Boyd JL, Harrop FM, Medeley P, Mindham RHS, Randall JI, Spokes EGS (1992) A controlled, longitudinal study of dementia in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 55: 566\u2013571.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"15_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00004714-199502001-00005","volume":"15","author":"RL Borison","year":"1995","unstructured":"Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15 [Suppl 1]: 24\u201329.","journal-title":"J Clin Psychopharmacol"},{"key":"15_CR16","first-page":"1321","volume":"20","author":"RL Borison","year":"1981","unstructured":"Borison RL, Fields JZ, Diamond BL (1981) Site-specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacol 20: 1321\u20131322.","journal-title":"Neuropharmacol"},{"key":"15_CR17","first-page":"213","volume":"28","author":"RL Borison","year":"1992","unstructured":"Borison RL, Rathiraja AP, Bruce I, et al. (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 28: 213\u2013218.","journal-title":"Psychopharmacol Bull"},{"key":"15_CR18","first-page":"1352","volume":"46","author":"RH Bouchard","year":"1989","unstructured":"Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side-effects. Am J Psychiatry 46: 1352\u20131253.","journal-title":"Am J Psychiatry"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1212\/WNL.25.8.701","volume":"25","author":"FP Bowen","year":"1975","unstructured":"Bowen FP, Kamienny RS, Burns MM, Yahr MD (1975) Parkinsonism: effect of levodopa treatment on concept formation. Neurology 25: 701\u2013704.","journal-title":"Neurology"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/brain\/109.5.987","volume":"109","author":"R Brown","year":"1986","unstructured":"Brown R, Marsden CD (1986) Visuospatial function in Parkinson\u2019s disease. Brain 109: 987\u20131002.","journal-title":"Brain"},{"key":"15_CR21","series-title":"Behavioural neurology of movement disorders","first-page":"61","volume-title":"Advances in neurology","author":"R Brown","year":"1995","unstructured":"Brown R, Jahnshahi M (1995) Depression in Parkinson\u2019s disease: a psychosocial viewpoint. In: Weiner WG, Lang AE (eds) Advances in neurology, vol 65. Behavioural neurology of movement disorders. Raven Press, New York, pp 61\u201384."},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0028-1094449","volume":"8","author":"HR B\u00fcrki","year":"1975","unstructured":"B\u00fcrki HR, Eichenberger E, Sayers AC, White TG (1975) Clozapine and the dopamine hypothesis of schizophrenia, a critical appraisal. Pharmakopsychiatr Neuropsychopharmakol 8: 115\u2013121.","journal-title":"Pharmakopsychiatr Neuropsychopharmakol"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/jnnp.58.1.51","volume":"58","author":"D Caparros-Lefebvre","year":"1995","unstructured":"Caparros-Lefebvre D, P\u00e9cheux N, Petit V, Duhamel A, Petit H (1995) Which factors predict cognitive decline in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 58: 51\u201355.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR24","first-page":"577","volume":"33","author":"GG Celesia","year":"1972","unstructured":"Celesia GG, Wanamaker WM (1972) Psychiatric disturbances in Parkinson\u2019s disease. Dis Nerv Syst 33: 577\u2013583.","journal-title":"Dis Nerv Syst"},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF00428197","volume":"85","author":"DLS Ceulemans","year":"1985","unstructured":"Ceulemans DLS, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PAJ (1985) Effects of serotonin antagonists on schizophrenia: a pilot study with setoperone. Psychopharmacol 85: 329\u2013332.","journal-title":"Psychopharmacol"},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/0022-510X(91)90193-B","volume":"106","author":"AVT Cheng","year":"1991","unstructured":"Cheng AVT, Ferrier IN, Morris CM, et al. (1991) Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer\u2019s and Parkinson\u2019s diseases. J Neurol Sci 106: 50\u201355.","journal-title":"J Neurol Sci"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0306-4522(93)90240-G","volume":"54","author":"G Chinaglia","year":"1993","unstructured":"Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993) Serotoninergic terminal transporters are differentially affected in Parkinson\u2019s disease and progressive supranuclear palsy: an autoradiographic study with (3H)citalopram. Neuroscience 54: 691\u2013699.","journal-title":"Neuroscience"},{"key":"15_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","volume":"13","author":"G Chouinard","year":"1993","unstructured":"Chouinard G, Jones B, Remington G, et al. (1993) Canadian multi-centre placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"15_CR29","first-page":"121","volume-title":"Sleep: neurotransmitters and neuromodulators","author":"C Cianchetti","year":"1985","unstructured":"Cianchetti C (1985) Dopamine agonists and sleep in man. In: Wauquier A, Gaillard JM, Monti JM, Radulovacki M (eds) Sleep: neurotransmitters and neuromodulators. Raven Press, New York, pp 121\u2013134."},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1600-0447.1992.tb01473.x","volume":"85","author":"A Claus","year":"1992","unstructured":"Claus A, Bollen J, De Cuyper H, et al. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic in-patients: a multi-centre, double-blind comparative study. Acta Psychiatr Scand 85: 295\u2013305.","journal-title":"Acta Psychiatr Scand"},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0165-1781(79)90062-3","volume":"1","author":"BM Cohen","year":"1979","unstructured":"Cohen BM, Herschel M, Aoba A (1979) Neuroleptic antimuscarinic and antiadrenergic activity of chlorpromazine, thioridazine and their metabolites. Psychiatry Res 1:199\u2013208.","journal-title":"Psychiatry Res"},{"key":"15_CR32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1176\/ajp.147.10.1374","volume":"147","author":"S Cohen","year":"1990","unstructured":"Cohen S, Chiles J, McNaughton A (1990) Weight gain associated with clozapine. Am J Psychiatry 147: 503\u2013504.","journal-title":"Am J Psychiatry"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/01688639308402591","volume":"15","author":"JA Cooper","year":"1993","unstructured":"Cooper JA, Sagar HJ (1993) Incidental and intentional recall in Parkinson\u2019s disease: an account based on diminished attentional resources. J Clin Exp Neuropsychol 15: 713\u2013731.","journal-title":"J Clin Exp Neuropsychol"},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/brain\/115.6.1701","volume":"115","author":"JA Cooper","year":"1992","unstructured":"Cooper JA, Sagar HJ, Doherty SM, et al. (1992) Different effects of dopaminergic and anticholinergic therapy on memory performance in Parkinson\u2019s disease. Brain 115: 1701\u20131725.","journal-title":"Brain"},{"issue":"Suppl 3","key":"15_CR35","first-page":"6","volume":"16","author":"PJ Cowen","year":"1993","unstructured":"Cowen PJ (1993) Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol 16 [Suppl 3]: 6\u201318.","journal-title":"Clin Neuropharmacol"},{"key":"15_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ana.410220207","volume":"22","author":"RJ D\u2019Amato","year":"1987","unstructured":"D\u2019Amato RJ, Zweig RM, Whitehouse PJ, et al. (1987) Aminergic systems in Alzheimer\u2019s disease and Parkinson\u2019s disease. Ann Neurol 22: 229\u2013236.","journal-title":"Ann Neurol"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0303-8467(95)00032-F","volume":"97","author":"RA Vos De","year":"1995","unstructured":"De Vos RA, Jansen EN, Stam FC, Ravid R, Swab DF (1995) \u201cLewy body disease\u201d: clinico-pathological correlations in 18 consecutive cases of Parkinson\u2019s disease with and without dementia. Clin Neurol Neurosurg 97: 12\u201322.","journal-title":"Clin Neurol Neurosurg"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1212\/WNL.45.4.753","volume":"45","author":"M Dogali","year":"1995","unstructured":"Dogali M, Fazzini E, Kolodny E, et al. (1995) Stereotactic ventral pallidotomy for Parkinson\u2019s disease. Neurology 45: 753\u2013761.","journal-title":"Neurology"},{"key":"15_CR39","series-title":"Parkinson\u2019s disease","first-page":"585","volume-title":"Advances in neurology","author":"M Dogali","year":"1996","unstructured":"Dogali M, Sterio D, Fazzini E, et al. (1996) Effects of posteroventral pallidotomy in Parkinson\u2019s disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson\u2019s disease. Lippincot-Raven, Philadelphia, pp 585\u2013590."},{"key":"15_CR40","first-page":"119","volume":"34","author":"EF Donelli","year":"1972","unstructured":"Donelli EF, Chase TN (1972) Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with 1-dopa. Dis Nerv Syst 34: 119\u2013123.","journal-title":"Dis Nerv Syst"},{"key":"15_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ana.410220108","volume":"22","author":"B Dubois","year":"1987","unstructured":"Dubois B, Danze F, Pilon B, et al. (1987) Cholinergic-dependent deficits in Parkinson\u2019s disease. Ann Neurol 22: 26\u201330.","journal-title":"Ann Neurol"},{"key":"15_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/0028-3932(94)00071-9","volume":"32","author":"ME Duncombe","year":"1994","unstructured":"Duncombe ME, Bradshaw JL, Iansek R, Phillips JG (1994) Parkinsonian patients without dementia or depression do not suffer from bradyphrenia as indexed by performance in mental rotation tasks with and without advance information. Neuropsychologia 32: 1383\u20131396.","journal-title":"Neuropsychologia"},{"key":"15_CR43","first-page":"311","volume":"26","author":"AS Eison","year":"1990","unstructured":"Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD (1990) Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 26: 311\u2013315.","journal-title":"Psychopharmacol Bull"},{"key":"15_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/mds.870070205","volume":"7","author":"SA Factor","year":"1992","unstructured":"Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson\u2019s disease. Mov Disord 7: 125\u2013131.","journal-title":"Mov Disord"},{"key":"15_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/mds.870050404","volume":"5","author":"SA Factor","year":"1990","unstructured":"Factor SA, McAlarney T, S\u00e1nchez-Ramos JR, Weiner WJ (1990) Sleep disorders and sleep effect in Parkinson\u2019s disease. Mov Disord 5: 280\u2013285.","journal-title":"Mov Disord"},{"key":"15_CR46","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1212\/WNL.44.3_Part_1.544","volume":"44","author":"SA Factor","year":"1994","unstructured":"Factor SA, Brown D, Molho ES, Podskalny GD (1994) Clozapine: a 2-year open trial in Parkinson\u2019s disease patients with psychosis. Neurology 44: 544\u2013546","journal-title":"Neurology"},{"key":"15_CR47","first-page":"115","volume-title":"Advances in neurology","author":"SA Factor","year":"1995","unstructured":"Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson\u2019s disease: drug-induced psychiatric states. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Raven Press, New York, pp 115\u2013138."},{"key":"15_CR48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0022-510X(71)90178-X","volume":"14","author":"S Fahn","year":"1971","unstructured":"Fahn S, Libsch LR, Cutler RW (1971) Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson\u2019s disease in their role in akinesia, rigidity, chorea and tremor. J Neurol Sci 14: 427\u2013455.","journal-title":"J Neurol Sci"},{"issue":"Suppl 17","key":"15_CR49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/S0007125000296888","volume":"160","author":"L Farde","year":"1992","unstructured":"Farde L, Nordstr\u00f6m A-L (1992) PET analysis indicates typical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 160 [Suppl 17]: 30\u201333.","journal-title":"Br J Psychiatry"},{"key":"15_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF00442555","volume":"99","author":"L Farde","year":"1989","unstructured":"Farde L, Wiesel FA, Nordstr\u00f6m A-L, Sedvall G (1989) Dl- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacol 99: 28\u201331.","journal-title":"Psychopharmacol"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1600-0404.1994.tb02676.x","volume":"90","author":"E Farina","year":"1994","unstructured":"Farina E, Cappa SF, Polimeni M, Magni E, Canesi M, Zechinelli A, Scarlato G, Mariani C (1994) Frontal dysfunction in early Parkinson\u2019s disease. Acta Neurol Scand 90: 34\u201338.","journal-title":"Acta Neurol Scand"},{"key":"15_CR52","first-page":"219","volume":"25","author":"JP Feighner","year":"1989","unstructured":"Feighner JP, Pambakian R, Fowler RC, et al. (1989) A comparison of nefazodone imipramine and placebo in patients with severe to moderate depression. Psychopharmacol Bull 25: 219\u2013221.","journal-title":"Psychopharmacol Bull"},{"key":"15_CR53","first-page":"222","volume":"51","author":"JP Feighner","year":"1990","unstructured":"Feighner JP, Boyer WF, Tyler DL, Neborsky RJ (1990) Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 51: 222\u2013225.","journal-title":"J Clin Psychiatry"},{"key":"15_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-Mental State\u201d, a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198","journal-title":"J Psychiatr Res"},{"issue":"3","key":"15_CR55","first-page":"45","volume":"16","author":"R Fontaine","year":"1993","unstructured":"Fontaine R (1993) Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 16 [Suppl 3]: 45\u201350.","journal-title":"Clin Neuropharmacol"},{"key":"15_CR56","first-page":"681","volume":"344","author":"B Ford","year":"1994","unstructured":"Ford B, Lynch T, Greene P (1994) Risperidone in Parkinson\u2019s disease. Lancet 344: 681.","journal-title":"Risperidone in Parkinson\u2019s disease. Lancet"},{"key":"15_CR57","first-page":"316","volume":"7","author":"D Fram","year":"1970","unstructured":"Fram D, Murphy D, Goodwin F, et al. (1970) L-Dopa and sleep in depressed patients. Psychophysiology 7: 316\u2013317.","journal-title":"Psychophysiology"},{"key":"15_CR58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00002826-199108000-00001","volume":"14","author":"JH Friedman","year":"1991","unstructured":"Friedman JH (1991) The management of the levodopa psychoses. Clin Neuropharmacol 14: 283\u2013295.","journal-title":"Clin Neuropharmacol"},{"key":"15_CR59","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.39.9.1219","volume":"39","author":"JH Friedman","year":"1989","unstructured":"Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson\u2019s disease. Neurology 39: 1219\u20131221.","journal-title":"Neurology"},{"key":"15_CR60","first-page":"1235","volume":"317","author":"EW Fungfeld","year":"1989","unstructured":"Fungfeld EW, Baggen M, Nedwidek P, et al. (1989) Double blind study with phosphatidylserine in parkinsonian patients with senile dementia of Alzheimer\u2019s type (SDAT). Prog Clin Biol Res 317: 1235\u20131246.","journal-title":"Prog Clin Biol Res"},{"key":"15_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-3223(91)90074-V","volume":"30","author":"A Gedye","year":"1991","unstructured":"Gedye A (1991) Buspirone alone or with serotonergic diet reduced aggression in a developmentally disabled adult. Biol Psychiatry 30: 88\u201391.","journal-title":"Biol Psychiatry"},{"key":"15_CR62","first-page":"S107","volume":"55","author":"J Gerlach","year":"1994","unstructured":"Gerlach J, Peacock L (1994) Motor and mental side-effects of clozapine. J Clin Psychiatry. 55 S B: S107\u2013S109.","journal-title":"J Clin Psychiatry"},{"key":"15_CR63","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/ana.410260403","volume":"26","author":"DC German","year":"1989","unstructured":"German DC, Menaye K, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson\u2019s disease: computer visualization. Ann Neurol 26: 507\u2013514.","journal-title":"Ann Neurol"},{"key":"15_CR64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1056\/NEJM199307153290312","volume":"329","author":"SL Gerson","year":"1993","unstructured":"Gerson SL (1993) Clozapine- deciphering the risks. N Engl J Med 329: 204\u2013205.","journal-title":"N Engl J Med"},{"key":"15_CR65","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1212\/WNL.43.11.2227","volume":"43","author":"CG Goetz","year":"1993","unstructured":"Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced. Parkinson\u2019s disease. Neurology 43: 2227\u20132229.","journal-title":"Neurology"},{"key":"15_CR66","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.870080317","volume":"8","author":"G G\u00f3mez Ar\u00e9valo","year":"1993","unstructured":"G\u00f3mez Ar\u00e9valo G, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson\u2019s disease: a preliminary study. Mov Disord 8: 349\u2013354.","journal-title":"Mov Disord"},{"key":"15_CR67","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1001\/jama.1971.03190260031009","volume":"218","author":"FK Goodwin","year":"1971","unstructured":"Goodwin FK (1971) Psychiatric side-effects of levodopa in man. JAMA 218: 1915\u20131920","journal-title":"JAMA"},{"key":"15_CR68","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/jnnp.49.4.381","volume":"49","author":"AM Gotham","year":"1986","unstructured":"Gotham AM, Brown RG, Marsden CD (1986) Depression in Parkinson\u2019s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49: 381\u2013389","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR69","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/0028-3908(91)90160-D","volume":"30","author":"G Gross","year":"1991","unstructured":"Gross G, Xin X, Gastpar M (1991) Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacol 30: 1159\u20131166.","journal-title":"Neuropharmacol"},{"key":"15_CR70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF02245449","volume":"114","author":"C Haring","year":"1994","unstructured":"Haring C, Neudorfer C, Schwitzer J, et al. (1994) EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacol 114: 97\u2013100.","journal-title":"Psychopharmacol"},{"key":"15_CR71","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00005053-197704000-00006","volume":"164","author":"R Halgin","year":"1977","unstructured":"Halgin R, Riklin M, Misiak H (1977) Levodopa, parkinsonism, and recent memory. J Nerv Ment Dis 164: 268\u2013272.","journal-title":"J Nerv Ment Dis"},{"key":"15_CR72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","volume":"510","author":"GM Halliday","year":"1990","unstructured":"Halliday GM, Blumbergs PC, Cotton RGH, et al. (1990) Loss of brainstem serotonin- and substance P- containing neurons in Parkinson\u2019s disease. Brain Res 510: 104\u2013107.","journal-title":"Brain Res"},{"key":"15_CR73","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/cncr.2820690533","volume":"69","author":"JR Halperin","year":"1992","unstructured":"Halperin JR, Murphy B (1992) Extrapyramidal reaction to ondansetron. Cancer 69: 1275","journal-title":"Cancer"},{"key":"15_CR74","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR75","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/1097-4679(197504)31:2<321::AID-JCLP2270310235>3.0.CO;2-1","volume":"31","author":"AR Harnel","year":"1975","unstructured":"Harnel AR, Riklan M (1975) Cognitive and perceptual effects of long range 1-dopa therapy in parkinsonism. J Clin Psychol 31: 321\u2013333.","journal-title":"J Clin Psychol"},{"key":"15_CR76","first-page":"37","volume-title":"Risperidone: major progress in antipsychotic treatment","author":"K Heinrich","year":"1991","unstructured":"Heinrich K, Klieser E, Lehmann E, Kinzier E (1991) Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. In: Kane JM (ed) Risperidone: major progress in antipsychotic treatment. Oxford Clinical Communications, Oxford, pp 37\u201339."},{"key":"15_CR77","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/jnnp.51.2.244","volume":"51","author":"M Hietanen","year":"1988","unstructured":"Hietanen M, Ter\u00e4v\u00e4inen H (1988) The effect of age of disease onset on neuropsychological performance in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 51: 244\u2013249.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR78","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1212\/WNL.37.8.1371","volume":"37","author":"SJ Huber","year":"1987","unstructured":"Huber SJ, Shulman HG, Paulson GW, Shuttleworth EC (1987) Fluctuations in plasma dopamine level impair memory in Parkinson\u2019s disease. Neurology 37: 1371\u20131375.","journal-title":"Neurology"},{"key":"15_CR79","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1212\/WNL.39.3.438","volume":"39","author":"SJ Huber","year":"1989","unstructured":"Huber SJ, Shulman HG, Paulson GW, Shuttleworth EC (1989) Dose-dependent memory impairment in Parkinson\u2019s disease. Neurology 39: 438\u2013440.","journal-title":"Neurology"},{"key":"15_CR80","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, et al. (1992) Accuracy of diagnosis of idiopathic Parkinson\u2019s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181\u2013184.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S0317167100027141","volume":"15","author":"TA Hurwitz","year":"1988","unstructured":"Hurwitz TA, Calne DB, Waterman K (1988) Treatment of dopaminomimetic psychosis in Parkinson\u2019s disease with electroconvulsive therapy. Can J Neurol Sci 15: 32\u201334","journal-title":"Can J Neurol Sci"},{"key":"15_CR82","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","volume":"ii","author":"J Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 J, Alhava E, Olkinuora M, Palva I (1975) Clozapine and agranulocytosis. Lancet ii: 611.","journal-title":"Lancet"},{"key":"15_CR83","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/BF02190411","volume":"244","author":"K Ikeguchi","year":"1995","unstructured":"Ikeguchi K, Kuroda A (1995) Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 244: 320\u2013324.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"15_CR84","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/365393a0","volume":"365","author":"LL Iversen","year":"1993","unstructured":"Iversen LL (1993) The D4 and schizophrenia. Nature 365: 393.","journal-title":"Nature"},{"key":"15_CR85","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1212\/WNL.40.10.1529","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, McDermott M, Carter J, et al. (1990) Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. Neurology 40: 1529\u20131534.","journal-title":"Neurology"},{"key":"15_CR86","first-page":"324","volume":"12","author":"PAJ Jansen","year":"1987","unstructured":"Jansen PAJ (1987) The development of new antipsychotic drugs: towards a new strategy in the management of chronic psychoses. J Drug Ther Res 12: 324\u2013328.","journal-title":"J Drug Ther Res"},{"key":"15_CR87","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1212\/WNL.43.1_Part_1.211","volume":"43","author":"ENH Jansen Steur","year":"1993","unstructured":"Jansen Steur ENH (1993) Increase of Parkinson disability after fluoxetine medication. Neurology 43: 211\u2013213.","journal-title":"Neurology"},{"key":"15_CR88","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1600-0404.1994.tb01677.x","volume":"89","author":"ENH Jansen","year":"1994","unstructured":"Jansen ENH (1994) Clozapine in the treatment of tremor in Parkinson\u2019s disease. Acta Neurol Scand 89: 262\u2013265.","journal-title":"Acta Neurol Scand"},{"key":"15_CR89","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/j.1471-4159.1981.tb10843.x","volume":"36","author":"F Javoy-Agid","year":"1981","unstructured":"Javoy-Agid F, Taquet H, Ploska A, et al. (1981) Distribution of catecholamines in the ventral mesencephalon of the human brain, with special reference to Parkinson\u2019s disease. J Neurochem 36: 2101\u20132105.","journal-title":"J Neurochem"},{"key":"15_CR90","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1212\/WNL.44.12.2406","volume":"44","author":"FJ Jim\u00e9nez-Jim\u00e9nez","year":"1994","unstructured":"Jim\u00e9nez-Jim\u00e9nez FJ, Tejeiro J, Mart\u00ednez-Junquera G, et al. (1994) Parkinsonism exacerbated by paroxetine. Neurology 44: 2406.","journal-title":"Neurology"},{"key":"15_CR91","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1600-0447.1985.tb01268.x","volume":"71","author":"U Juul-Povlsen","year":"1985","unstructured":"Juul-Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients, treated with clozapine for up to 12 years. Acta Psychiatr Scand 71: 176\u2013185.","journal-title":"Acta Psychiatr Scand"},{"key":"15_CR92","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0014-2999(76)90340-X","volume":"38","author":"S Kafi","year":"1976","unstructured":"Kafi S, Gaillard J (1976) Brain dopamine receptors and sleep in the rat: effects of stimulation and blockade. Eur J Pharmacol 38: 357\u2013363.","journal-title":"Eur J Pharmacol"},{"key":"15_CR93","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1176\/jnp.4.4.454","volume":"4","author":"LP Karper","year":"1992","unstructured":"Karper LP, Salloway SP, Seibyl JP, Krystal JH (1992) Prolonged post-ictal encephalopathy in two patients with clozapine induced seizures. J Neuropsychiatry Clin Neurosci 4: 454\u2013457.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"15_CR94","first-page":"448","volume":"119","author":"AM Kazee","year":"1995","unstructured":"Kazee AM, Han LY (1995) Cortical Lewy bodies in Alzheimer\u2019s disease. Arch Path Lab Med 119: 448\u2013453.","journal-title":"Arch Path Lab Med"},{"key":"15_CR95","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1212\/WNL.44.9.1756","volume":"44","author":"K Kieburtz","year":"1994","unstructured":"Kieburtz K, McDermott M, Como P, et al. (1994) The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson\u2019s disease. Neurology 44: 1756\u20131759.","journal-title":"Neurology"},{"key":"15_CR96","first-page":"117","volume":"27","author":"HL Klawans","year":"1988","unstructured":"Klawans HL (1988) Psychiatric side-effects during the treatment of Parkinson\u2019s disease. J Neural Transm 27 [Suppl]: 117\u2013122.","journal-title":"J Neural Transm"},{"key":"15_CR97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0010-9452(84)80051-9","volume":"20","author":"WC Koller","year":"1984","unstructured":"Koller WC (1984) Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy. Cortex 20: 307\u2013311.","journal-title":"Cortex"},{"issue":"17","key":"15_CR98","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1192\/S0007125000296906","volume":"160","author":"P Krupp","year":"1992","unstructured":"Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J. Psychiatry 160 [Suppl 17]: 38\u201340.","journal-title":"Br J. Psychiatry"},{"key":"15_CR99","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1212\/WNL.37.3.477","volume":"37","author":"AE Lang","year":"1987","unstructured":"Lang AE, Johnson K (1987) Akathisia in idiopathic Parkinson\u2019s disease. Neurology 37: 477\u2013481.","journal-title":"Neurology"},{"key":"15_CR100","first-page":"301","volume":"34","author":"AE Lang","year":"1993","unstructured":"Lang AE, Sandor P, Duff J (1993) Remoxipride in Parkinson\u2019s disease: differential response in patients with dyskinesias\/fluctuations vs. psychosis. Ann Neurol 34: 301\u2013302 (Abstract).","journal-title":"Ann Neurol"},{"key":"15_CR101","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1136\/bmj.305.6862.1160-c","volume":"305","author":"M Launer","year":"1992","unstructured":"Launer M (1992) Diarrhoea during treatment with clozapine. Br Med J 305: 1160.","journal-title":"Br Med J"},{"key":"15_CR102","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/jnp.3.4.412","volume":"3","author":"BE Levin","year":"1991","unstructured":"Levin BE, Llabre MM, Reisman S (1991) A retrospective analysis of the effects of anticholinergic medication on memory performance in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci 3: 412\u2013416.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"15_CR103","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1532-5415.1993.tb06743.x","volume":"41","author":"MF Lew","year":"1993","unstructured":"Lew MF, Waters CH (1993) Clozapine treatment of parkinsonism with psychosis. J Am Geriatr Soc 41: 669\u2013671.","journal-title":"J Am Geriatr Soc"},{"key":"15_CR104","first-page":"339","volume":"50","author":"JF Lipinski Jr","year":"1989","unstructured":"Lipinski JF Jr, Mallya G, Zimmerman, Pope HG Jr (1989) Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 339\u2013342.","journal-title":"J Clin Psychiatry"},{"key":"15_CR105","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(76)91816-X","volume":"ii","author":"S Lipper","year":"1976","unstructured":"Lipper S (1976) Psychosis in patients on bromocriptine and levodopa with carbidopa. Lancet ii: 571\u2013572.","journal-title":"Lancet"},{"key":"15_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/jnnp.54.1.25","volume":"54","author":"I Litvan","year":"1991","unstructured":"Litvan I, Mohr E, Williams J, Fedio P, Chase TN (1991) Differential memory and executive functions in demented patients with Parkinson\u2019s and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 54: 25\u201329.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR107","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(94)92696-4","volume":"343","author":"MG Livingston","year":"1994","unstructured":"Livingston MG (1994) Risperidone. Lancet 343: 457\u2013460.","journal-title":"Lancet"},{"key":"15_CR108","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(95)92404-3","volume":"346","author":"AM Lozano","year":"1995","unstructured":"Lozano AM, Lang AE, G\u00e1lvez-Jim\u00e9nez N, et al. (1995) Effect of GPi pallidotomy on motor function in Parkinson\u2019s disease. Lancet 346: 1383\u20131387.","journal-title":"Lancet"},{"key":"15_CR109","first-page":"96","volume-title":"Movement disorders","author":"CD Marsden","year":"1982","unstructured":"Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson\u2019s disease: clinical aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, London, pp 96\u2013122."},{"key":"15_CR110","first-page":"293","volume-title":"Neurotransmisi\u00f3n y plasticidad sin\u00e1ptica","author":"MJ Mart\u00ed","year":"1991","unstructured":"Mart\u00ed MJ, Tolosa E (1991) Demencia en la enfermedad de Parkinson y en la enfermedad de Alzheimer: similitudes y diferencias. In: Esquerda JE, Gallego R, Gual A, Ram\u00edrez G, Rubia F (eds) Neurotransmisi\u00f3n y plasticidad sin\u00e1ptica. Espaxs, Barcelona, pp 293\u2013309."},{"key":"15_CR111","series-title":"Behavioral neurology of movement disorders","first-page":"49","volume-title":"Advances in neurology","author":"HS Mayberg","year":"1995","unstructured":"Mayberg HS, Solomon DH (1995) Depression in Parkinson\u2019s disease: a biochemical and organic viewpoint. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Behavioral neurology of movement disorders. Raven Press, New York, pp 49\u201360."},{"key":"15_CR112","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/ana.410280111","volume":"28","author":"HS Mayberg","year":"1990","unstructured":"Mayberg HS, Starkstein SE, Sadzot B, et al. (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson\u2019s disease. Ann Neurol 28: 57\u201364.","journal-title":"Ann Neurol"},{"key":"15_CR113","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1212\/WNL.31.6.645","volume":"31","author":"R Mayeux","year":"1981","unstructured":"Mayeux R, Stern Y, Rosen J, Leventhal J (1981) Depression, intellectual impairment, and Parkinson\u2019s disease. Neurology 31: 645\u2013650.","journal-title":"Neurology"},{"key":"15_CR114","first-page":"756","volume":"143","author":"R Mayeux","year":"1984","unstructured":"Mayeux R, Stern Y, Cote L, Williams JBW (1984) Altered serotonin metabolism in depressed patients in Parkinson\u2019s disease. Am J Psychiatry 143: 756\u2013759","journal-title":"Am J Psychiatry"},{"key":"15_CR115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.143.6.756","volume":"143","author":"R Mayeux","year":"1986","unstructured":"Mayeux R, Stern Y, Williams JBW, et al. (1986) Clinical and biochemical features of depression in Parkinson\u2019s disease. Am J Psychiatry 143: 756\u2013759.","journal-title":"Am J Psychiatry"},{"key":"15_CR116","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","volume":"49","author":"R Mayeux","year":"1992","unstructured":"Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang M-X, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson\u2019s disease with and without dementia. Arch Neurol 49: 492\u2013497.","journal-title":"Arch Neurol"},{"key":"15_CR117","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1212\/WNL.42.9.1813","volume":"42","author":"EF McCance-Katz","year":"1992","unstructured":"McCance-Katz EF, Marek KL, Price LH (1992) Serotonergic dysfunction in depression associated with Parkinson\u2019s disease. Neurology 42: 1813\u20131814.","journal-title":"Neurology"},{"issue":"3","key":"15_CR118","first-page":"441","volume":"42","author":"HP McDermott","year":"1992","unstructured":"McDermott HP, Jankovic J, Parkinson Study Group (1992) Factors predictive of the need for levodopa therapy in early, untreated Parkinson\u2019s disease. Neurology 42 [Suppl 3]: 441","journal-title":"Neurology"},{"key":"15_CR119","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S0140-6736(94)92511-9","volume":"343","author":"G Meco","year":"1994","unstructured":"Meco G, Alessandria A, Binfati V, Giustini P (1994) Risperidone for hallucinations in levodopa-treated Parkinson\u2019s disease patients. Lancet 343: 1370\u20131371.","journal-title":"Lancet"},{"key":"15_CR120","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF02245439","volume":"114","author":"AAHP Megens","year":"1994","unstructured":"Megens AAHP, Awouters FHL, Schotte A, et al. (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacol 114: 9\u201323.","journal-title":"Psychopharmacol"},{"key":"15_CR121","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1001\/jama.1970.03170290061017","volume":"213","author":"MJ Meier","year":"1970","unstructured":"Meier MJ, Martin WE (1970) Intellectual changes associated with levodopa therapy. JAMA 213: 456\u2013466.","journal-title":"JAMA"},{"key":"15_CR122","first-page":"406","volume":"8","author":"E Melamed","year":"1993","unstructured":"Melamed E, Zoldan J, Friedberg G, Goldberg-Stein H (1993) Is hallucinosis in Parkinson\u2019s disease due to central serotonergic hyperactivity? Mov Disord 8: 406\u2013407.","journal-title":"Mov Disord"},{"key":"15_CR123","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0193-953X(18)30179-5","volume":"16","author":"HY Meltzer","year":"1993","unstructured":"Meltzer HY (1993) New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 16: 365\u2013385.","journal-title":"Psychiatr Clin North Am"},{"issue":"Suppl","key":"15_CR124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1600-0447.1989.tb06432.x","volume":"352","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Koenig JL, Nash JF, Gudelsky GA (1989a) Melperone and clozapine: neuroendocrine effects of typical neuroleptic drugs. Acta Psychiatr Scand 352 [Suppl]: 24\u201329.","journal-title":"Acta Psychiatr Scand"},{"key":"15_CR125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, LeeJ-C (1989b) Classification of typical and atypical antipsychotic drugs on the basis of dopamine Dl, D2 and serotonin-2 pKi values. J Pharmacol Exp Ther 251: 238\u2013246.","journal-title":"J Pharmacol Exp Ther"},{"key":"15_CR126","first-page":"39","volume":"12","author":"HY Meltzer","year":"1995","unstructured":"Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson\u2019s disease. A high potency effect of clozapine. Neuropsychopharmacol 12: 39\u201345.","journal-title":"Neuropsychopharmacol"},{"key":"15_CR127","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/mds.870090213","volume":"9","author":"T Mendis","year":"1994","unstructured":"Mendis T, Mohr E, George A, et al. (1994) Symptomatic relief from treatment-induced psychosis in Parkinson\u2019s disease: an open-label pilot study with remoxipride. Mov Disord 9: 197\u2013200.","journal-title":"Mov Disord"},{"key":"15_CR128","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.33.2.188","volume":"33","author":"RHS Mindham","year":"1970","unstructured":"Mindham RHS (1970) Psychiatric symptoms in parkinsonism. J Neurol Neurosurg Psychiatry 33:181\u2013191.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR129","series-title":"Behavioral neurology of movement disorders","first-page":"97","volume-title":"Advances in neurology","author":"E Mohr","year":"1995","unstructured":"Mohr E, Mendis T, Grimes DJ (1995) Late cognitive changes in Parkinson\u2019s disease with emphasis on dementia. In: Weiner WJ, Lang AE (eds) Advances in neurology, vol 65. Behavioral neurology of movement disorders. Raven Press, New York, pp 97\u2013113."},{"key":"15_CR130","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF02259665","volume":"9","author":"SP Molinari","year":"1995","unstructured":"Molinari SP, Kaminski R, Di Rocco A, Yahr MD (1995) The use of famotidine in the treatment of Parkinson\u2019s disease: a pilot study. J Neural Transm [P-D Sect] 9: 243\u2013247.","journal-title":"J Neural Transm [P-D Sect]"},{"issue":"1","key":"15_CR131","first-page":"99","volume":"9","author":"JL Montastruc","year":"1994","unstructured":"Montastruc JL, Fabre N, Blin O, et al. (1994) Does fluoxetine aggravate Parkinson\u2019s disease? A pilot prospective trial. Mov Disord 9 [Suppl 1]: 99.","journal-title":"Mov Disord"},{"key":"15_CR132","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00176857","volume":"94","author":"NA Moore","year":"1988","unstructured":"Moore NA, Axton MS (1988) Production of climbing behaviour in mice requires both Dl and D2 receptor activation. Psychopharmacol 94: 263\u2013266.","journal-title":"Psychopharmacol"},{"key":"15_CR133","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0022-3565(25)10792-1","volume":"262","author":"NA Moore","year":"1992","unstructured":"Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel \u201catypical\u201d antipsychotic agent. J Pharmacol Exp Ther 262: 545\u2013551","journal-title":"J Pharmacol Exp Ther"},{"key":"15_CR134","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF02245453","volume":"114","author":"S Moore","year":"1994","unstructured":"Moore S, Kenyon P (1994) Atypical antipsychotics, clozapine and sulpiride do not antagonise amphetamine-induced stereotyped locomotion. Psychopharmacol 114: 123\u2013130.","journal-title":"Psychopharmacol"},{"key":"15_CR135","first-page":"6","volume":"135","author":"C Moskovitz","year":"1978","unstructured":"Moskovitz C, Moses H, Klawans H(1978) Levodopa induced psychosis: a kindling phenomena. Am J Psychiatry 135: 6\u201310.","journal-title":"Am J Psychiatry"},{"key":"15_CR136","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S0140-6736(88)90986-5","volume":"ii","author":"T M\u00fcller","year":"1988","unstructured":"M\u00fcller T, Becker T, Fritze J (1988) Neuroleptic malignant syndrome after clozapine plus carbamacepine. Lancet ii: 1500.","journal-title":"Lancet"},{"issue":"17","key":"15_CR137","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1192\/S0007125000296931","volume":"160","author":"D Naber","year":"1992","unstructured":"Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 [Suppl 17]: 54\u201359","journal-title":"Br J Psychiatry"},{"key":"15_CR138","series-title":"Parkinson\u2019s disease","first-page":"557","volume-title":"Advances in neurology","author":"H Narabayashi","year":"1996","unstructured":"Narabayashi H (1996) Does stereotactic treatment of Parkinson\u2019s disease slow the progression of the disease? In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson\u2019s disease. Lippincot-Raven, Philadelphia, pp 557\u2013562."},{"key":"15_CR139","first-page":"451","volume-title":"Handbook of Parkinson\u2019s disease","author":"PA Nausieda","year":"1992","unstructured":"Nausieda PA (1992) Sleep in Parkinson\u2019s disease. In: Koller WC (ed) Handbook of Parkinson\u2019s disease. Marcel Dekker, New York, pp 451\u2013467."},{"key":"15_CR140","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00002826-198205020-00003","volume":"5","author":"PA Nausieda","year":"1982","unstructured":"Nausieda PA, Weiner WJ, Kaplan LR, Weber S, Klawans HL (1982) Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol 5: 183\u2013194.","journal-title":"Clin Neuropharmacol"},{"key":"15_CR141","series-title":"Experimental therapeutics of movement disorders","first-page":"23","volume-title":"Advances in neurology","author":"P Nausieda","year":"1983","unstructured":"Nausieda P, Tanner C, Klawans H (1983) Serotonergically active agents in the treatment of the levodopa induced psychosis. In: Fahn S, Calne DB, Shoulson I (eds) Advances in neurology, vol 37. Experimental therapeutics of movement disorders. Raven Press, New York, pp 23\u201332."},{"issue":"2","key":"15_CR142","first-page":"A219","volume":"44","author":"PA Nausieda","year":"1994","unstructured":"Nausieda PA, Leo GJ, Chesney D (1994) Comparison of conventional and Sinemet CR on the sleep of parkinsonian patients. Neurology 44 [Suppl 2]: A219.","journal-title":"Neurology"},{"key":"15_CR143","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.38.10.1553","volume":"38","author":"JG Nutt","year":"1988","unstructured":"Nutt JG, Gancher ST, Woodward WR (1988) Does inhibitory action of levodopa contribute to motor fluctuations? Neurology 38: 1553\u20131557.","journal-title":"Neurology"},{"key":"15_CR144","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1600-0404.1988.tb03668.x","volume":"78","author":"K Ostergaard","year":"1988","unstructured":"Ostergaard K, Dupond E (1988) Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson\u2019s disease. Acta Neurol Scand 78: 349\u2013350.","journal-title":"Acta Neurol Scand"},{"key":"15_CR145","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/BF00867426","volume":"242","author":"E Palazzini","year":"1995","unstructured":"Palazzini E, Soliveri P, Filippini G, et al. (1995) Progression of motor and cognitive impairment in Parkinson\u2019s disease. J Neurol 242: 535\u2013540.","journal-title":"J Neurol"},{"key":"15_CR146","volume-title":"Whittingham and Rowland for Sherwood, Neely, and Jones","author":"J Parkinson","year":"1817","unstructured":"Parkinson J (1817) An essay on the shaking palsy. Whittingham and Rowland for Sherwood, Neely, and Jones, London."},{"key":"15_CR147","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"Parkinson Study Group","year":"1993","unstructured":"Parkinson Study Group (1993) Effect of deprenyl and tocopherol on the progression of disability in early Parkinson\u2019s disease. N Engl J Med 328: 176\u2013183.","journal-title":"N Engl J Med"},{"key":"15_CR148","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/mds.870050310","volume":"5","author":"RF Pfeiffer","year":"1990","unstructured":"Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson\u2019s disease. Mov Disord 5: 239\u2013242.","journal-title":"Mov Disord"},{"key":"15_CR149","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0140-6736(92)90467-H","volume":"340","author":"LS Pilowski","year":"1992","unstructured":"Pilowski LS, Costa DC, Elli PJ, et al. (1992) Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340: 199\u2013202.","journal-title":"Lancet"},{"key":"15_CR150","first-page":"493","volume-title":"Parkinson\u2019s disease and movement disorders","author":"FJ Pirozzolo","year":"1993","unstructured":"Pirozzolo FJ, Swihart AA, Rey GJ, Mahurin R, Jankovic J (1993) Cognitive impairments associated with Parkinson\u2019s disease and other movement disorders. In: Jankovic J, Tolosa E (eds) Parkinson\u2019s disease and movement disorders. Williams & Wilkins, Baltimore, pp 493\u2013510."},{"key":"15_CR151","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/00005053-198608000-00010","volume":"174","author":"HG Pope Jr","year":"1986","unstructured":"Pope HG Jr, Cole JO, Choras PT, Fulwiler CE (1986) Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis 174: 493\u2013495.","journal-title":"J Nerv Ment Dis"},{"issue":"3","key":"15_CR152","first-page":"419","volume":"42","author":"AH Rajput","year":"1992","unstructured":"Rajput AH, Pahwa R, Pahwa P (1992) Mode of onset and prognosis in Parkinson\u2019s disease. Neurology 42 [Suppl 3]: 419.","journal-title":"Neurology"},{"key":"15_CR153","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0014-2999(84)90478-3","volume":"103","author":"E Richelson","year":"1984","unstructured":"Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vivo. Eur J Pharmacol 103: 197\u2013204.","journal-title":"Eur J Pharmacol"},{"key":"15_CR154","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1192\/bjp.165.3.333","volume":"165","author":"H Ring","year":"1994","unstructured":"Ring H, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ (1994) Depression in Parkinson\u2019s disease. Br J Psychiatry 165: 333\u2013339.","journal-title":"Br J Psychiatry"},{"key":"15_CR155","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0404.1983.tb01513.x","volume":"95","author":"UK Rinne","year":"1983","unstructured":"Rinne UK (1983) Problems associated with long term levodopa treatment of Parkinson\u2019s disease. Acta Neurol Scand 95: 19\u201326.","journal-title":"Acta Neurol Scand"},{"key":"15_CR156","first-page":"125","volume":"19","author":"RG Robinson","year":"1988","unstructured":"Robinson RG (1988) Post-stroke depression and lesion location. Stroke 19: 125.","journal-title":"Post-stroke depression and lesion location. Stroke"},{"key":"15_CR157","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/0014-2999(88)90121-5","volume":"148","author":"M Rubinstein","year":"1988","unstructured":"Rubinstein M, Gershanik OS, Stefano FJE (1988) Different roles of Dl and D2 dopamine receptors involved in locomotor activity in supersensitive mice. Eur J Pharmacol 148: 419\u2013426.","journal-title":"Eur J Pharmacol"},{"key":"15_CR158","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/0006-2952(85)90577-5","volume":"34","author":"NMJ Rupniak","year":"1985","unstructured":"Rupniak NMJ, Hall MD, Mann S, et al. (1985) Chronic treatment of clozapine, unlike haloperidol, does not induce changes in D-2 receptor function in the rat. Biochem Pharmacol 34: 2755\u20132763.","journal-title":"Biochem Pharmacol"},{"key":"15_CR159","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1001\/archneur.1982.00510220064017","volume":"39","author":"MS Sadeh","year":"1982","unstructured":"Sadeh MS, Braham J, Modan M (1982) Effects of anticholinergic drugs on memory in Parkinson\u2019s disease. Arch Neurol 39: 666\u2013667.","journal-title":"Arch Neurol"},{"key":"15_CR160","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/mds.870050308","volume":"5","author":"M Sano","year":"1990","unstructured":"Sano M, Stern Y, Marder K, Mayeux R (1990) A controlled trial of piracetam in intellectually impaired patients with Parkinson\u2019s disease. Mov Disord 5: 230\u2013234.","journal-title":"Mov Disord"},{"key":"15_CR161","first-page":"217","volume-title":"Parkinson\u2019s disease","author":"J Santamaria","year":"1992","unstructured":"Santamaria J, Tolosa E (1992) Clinical subtypes of Parkinson\u2019s disease and depression. In: Huber SG, Cummings JL (eds) Parkinson\u2019s disease. Neurobehavioral aspects. Oxford University Press, New York, pp 217\u2013228."},{"key":"15_CR162","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/WNL.36.8.1130","volume":"36","author":"J Santamaria","year":"1986","unstructured":"Santamaria J, Tolosa E, Vall\u00e9s A (1986) Parkinson\u2019s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36: 1130\u20131133.","journal-title":"Neurology"},{"key":"15_CR163","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF01579073","volume":"43","author":"B Scharf","year":"1978","unstructured":"Scharf B, Moskowitz C, Moses H, Luptom M, Klawans H (1978) Dream phenomena induced by chronic levodopa therapy. J Neural Transm 43: 143\u2013151.","journal-title":"J Neural Transm"},{"key":"15_CR164","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/BF00380972","volume":"235","author":"E Scholz","year":"1985","unstructured":"Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry 235: 60\u201364.","journal-title":"Eur Arch Psychiatry"},{"key":"15_CR165","first-page":"261","volume":"7","author":"P Seeman","year":"1992","unstructured":"Seeman P (1992) Dopamine receptor sequences, therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacol 7: 261\u2013284.","journal-title":"Neuropsychopharmacol"},{"key":"15_CR166","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/365441a0","volume":"365","author":"P Seeman","year":"1993","unstructured":"Seeman P, Guan HC, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441\u2013445.","journal-title":"Nature"},{"key":"15_CR167","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0140-6736(93)92594-J","volume":"341","author":"S Shaikh","year":"1993","unstructured":"Shaikh S, Coller D, Kerwin RW, et al. (1993) Dopamine D4 receptor subtypes and response to clozapine. Lancet 341: 116.","journal-title":"Lancet"},{"key":"15_CR168","first-page":"283","volume":"49","author":"KM Shaw","year":"1980","unstructured":"Shaw KM, Lees AJ, Stern GM (1980) The impact of treatment with levodopa on Parkinson\u2019s disease. Q J Med 49: 283\u2013293.","journal-title":"Q J Med"},{"key":"15_CR169","first-page":"61","volume":"13","author":"DR Sibley","year":"1992","unstructured":"Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. TIPS 13: 61\u201369.","journal-title":"TIPS"},{"key":"15_CR170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1176\/ajp.135.12.1585","volume":"135","author":"GM Simpson","year":"1978","unstructured":"Simpson GM, Cooper TA (1978) Clozapine plasma levels and convulsions. Am J Psychiatry 135: 99\u2013100.","journal-title":"Am J Psychiatry"},{"key":"15_CR171","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJM199211263272201","volume":"327","author":"DD Spencer","year":"1992","unstructured":"Spencer DD, Robbins RJ, Naftolin F, et al. (1992) Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson\u2019s disease. N Engl J Med 327: 1541\u20131548.","journal-title":"N Engl J Med"},{"key":"15_CR172","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/brain\/112.5.1141","volume":"112","author":"SE Starkstein","year":"1989","unstructured":"Starkstein SE, Preziosi TJ, Berthier ML, et al. (1989) Depression and cognitive impairment in Parkinson\u2019s disease. Brain 112: 1141\u20131153.","journal-title":"Brain"},{"key":"15_CR173","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/jnnp.53.7.597","volume":"53","author":"SE Starkstein","year":"1990","unstructured":"Starkstein SE, Bolduc PL, Mayberg HS, Preziosi TJ, Robinson RG (1990) Cognitive impairment and depression in Parkinson\u2019s disease: a follow-up study. J Neurol Neurosurg Psychiatry 53: 59\u2013602.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15_CR174","first-page":"1192","volume":"50","author":"Y Stern","year":"1993","unstructured":"Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson\u2019s disease. Neurology 50: 1192\u20131196.","journal-title":"Neurology"},{"key":"15_CR175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/ajp.147.2.252-a","volume":"147","author":"MB Stein","year":"1990","unstructured":"Stein MB, Heuser IJ, Juncos JL, Uhde TW (1990) Anxiety disorders in patients with Parkinson\u2019s disease. Am J Psychiatry 147: 217\u2013220.","journal-title":"Am J Psychiatry"},{"key":"15_CR176","series-title":"Parkinson\u2019s disease","first-page":"563","volume-title":"Advances in neurology","author":"RR Tasker","year":"1996","unstructured":"Tasker RR, DeCarvalho GC, Li CS, Kestle JRW (1996) Does thalamotomy alter the course of Parkinson\u2019s disease? In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson\u2019s disease. Lippincot-Raven, Philadelphia, pp 563\u2013584."},{"key":"15_CR177","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00179933","volume":"93","author":"DR Thomas","year":"1987","unstructured":"Thomas DR, Nelson DR, Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berlin) 93: 193\u2013200.","journal-title":"Psychopharmacology (Berlin)"},{"key":"15_CR178","first-page":"138","volume":"149","author":"P Thomas","year":"1992","unstructured":"Thomas P, Goudeman M (1992) Seizures with low doses of clozapine. Am J Psychiatry 149: 138\u2013139.","journal-title":"Am J Psychiatry"},{"key":"15_CR179","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1212\/WNL.45.4.705","volume":"45","author":"F Tison","year":"1995","unstructured":"Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alp\u00e9rovitcj A (1995) Dementia in Parkinson\u2019s disease: a population-based study in ambulatory and instutionalized individuals. Neurology 45: 705\u2013708.","journal-title":"Neurology"},{"issue":"6","key":"15_CR180","first-page":"35","volume":"44","author":"E Tolosa","year":"1994","unstructured":"Tolosa E, Valldeoriola F, Mart\u00ed MJ (1994) New and emerging strategies for improving levodopa treatment. Neurology 44 [Suppl 6]: 35\u201344.","journal-title":"Neurology"},{"key":"15_CR181","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.45.4.672","volume":"45","author":"AI Tr\u00f6ster","year":"1995","unstructured":"Tr\u00f6ster AI, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC (1995) The influence of depression on cognition in Parkinson\u2019s disease: a pattern of impairment distinguishable from Alzheimer\u2019s disease. Neurology 45: 672\u2013676.","journal-title":"Neurology"},{"key":"15_CR182","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF02245444","volume":"114","author":"LEC Beijsterveldt Van","year":"1994","unstructured":"Van Beijsterveldt LEC, Geerts RJF, Leysen JE, et al. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacol 114: 53\u201362.","journal-title":"Psychopharmacol"},{"key":"15_CR183","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00002826-199310000-00006","volume":"16","author":"G Herwaarden Van","year":"1993","unstructured":"Van Herwaarden G, Berger HJC, Horstink MWIM (1993) Short-term memory in Parkinson\u2019s disease after withdrawel of long-term anticholinergic therapy. Clin Neuropharmacol 16: 438\u2013443.","journal-title":"Clin Neuropharmacol"},{"key":"15_CR184","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"HHM Tol Van","year":"1991","unstructured":"Van Tol HHM, Bunzow JR, Guan HC, et al. (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610\u2013619.","journal-title":"Nature"},{"key":"15_CR185","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1212\/WNL.38.6.961","volume":"38","author":"JM Walker","year":"1988","unstructured":"Walker JM, Matsumoto RR, Bowen WD, Gans DL, Jones KD, Walker FO (1988) Evidence for a role of haloperidol-sensitive sigma \u201copiate\u201d receptors in the motor effects of antipsychotic drugs. Neurology 38: 961\u2013965.","journal-title":"Neurology"},{"key":"15_CR186","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1017\/S031716710004124X","volume":"21","author":"CH Waters","year":"1994","unstructured":"Waters CH (1994) Fluoxetine and selegiline: lack of significant interaction. Can J Neurol Sci 21: 259\u2013261.","journal-title":"Can J Neurol Sci"},{"key":"15_CR187","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/0140-6736(91)92851-R","volume":"337","author":"A White","year":"1991","unstructured":"White A, Corn TH, Feetham, Faulconbridge C (1991) Ondansetron in treatment of schizophrenia. Lancet 337: 1173.","journal-title":"Lancet"},{"key":"15_CR188","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF02245441","volume":"114","author":"FA Wiesel","year":"1994","unstructured":"Wiesel FA, Nordstr\u00f6m AL, Farde L, Eriksson B (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacol 114: 31\u201338.","journal-title":"Psychopharmacol"},{"key":"15_CR189","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/ageing\/18.1.11","volume":"18","author":"JA Wilson","year":"1989","unstructured":"Wilson JA, Smith RG (1989) The prevalence and aetiology of long term L-dopa side-effects in elderly parkinsonian patients. Age Ageing 18: 11\u201316.","journal-title":"Age Ageing"},{"key":"15_CR190","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1212\/WNL.40.5.832","volume":"40","author":"EC Wolters","year":"1990","unstructured":"Wolters EC, Hurwitz TA, Mak E, et al. (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40: 832\u2013834.","journal-title":"Neurology"},{"key":"15_CR191","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RS, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21: 343\u2013354.","journal-title":"Arch Neurol"},{"key":"15_CR192","first-page":"60","volume":"31","author":"JA Yaryura-Tobias","year":"1970","unstructured":"Yaryura-Tobias JA, Diamond B, Merlis S (1970) Psychiatric manifestations of levodopa. Dis Nerv Syst 31: 60\u201363.","journal-title":"Dis Nerv Syst"},{"key":"15_CR193","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0140-6736(93)90327-D","volume":"341","author":"J Zoldan","year":"1993","unstructured":"Zoldan J, Friedberg G, Goldberg-Stern, Melamed E (1993) Ondansentron for hallucinosis in advanced Parkinson\u2019s disease. Lancet 341: 562\u2013563.","journal-title":"Lancet"},{"key":"15_CR194","series-title":"Parkinson\u2019s disease","first-page":"541","volume-title":"Advances in neurology","author":"J Zoldan","year":"1996","unstructured":"Zoldan J, Friedberg G, Weizman A, Melamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson\u2019s disease. In: Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds) Advances in neurology, vol 69. Parkinson\u2019s disease. Lippincott-Raven, Philadelphia, pp 541\u2013544."}],"container-title":["Journal of Neural Transmission. Supplementa","Dementia in Parkinsonism"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-7091-6846-2_15.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T20:48:50Z","timestamp":1744231730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-7091-6846-2_15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997]]},"ISBN":["9783211829592","9783709168462"],"references-count":194,"URL":"https:\/\/doi.org\/10.1007\/978-3-7091-6846-2_15","relation":{},"ISSN":["0303-6995"],"issn-type":[{"type":"print","value":"0303-6995"}],"subject":[],"published":{"date-parts":[[1997]]}}}